Literature DB >> 16111578

Proton beam radiotherapy of iris melanoma.

Bertil Damato1, Andrzej Kacperek, Mona Chopra, Martin A Sheen, Ian R Campbell, R Douglas Errington.   

Abstract

PURPOSE: To report on outcomes after proton beam radiotherapy of iris melanoma. METHODS AND MATERIALS: Between 1993 and 2004, 88 patients with iris melanoma received proton beam radiotherapy, with 53.1 Gy in 4 fractions.
RESULTS: The patients had a mean age of 52 years and a median follow-up of 2.7 years. The tumors had a median diameter of 4.3 mm, involving more than 2 clock hours of iris in 32% of patients and more than 2 hours of angle in 27%. The ciliary body was involved in 20%. Cataract was present in 13 patients before treatment and subsequently developed in another 18. Cataract had a 4-year rate of 63% and by Cox analysis was related to age (p = 0.05), initial visual loss (p < 0.0001), iris involvement (p < 0.0001), and tumor thickness (p < 0.0001). Glaucoma was present before treatment in 13 patients and developed after treatment in another 3. Three eyes were enucleated, all because of recurrence, which had an actuarial 4-year rate of 3.3% (95% CI 0-8.0%).
CONCLUSIONS: Proton beam radiotherapy of iris melanoma is well tolerated, the main problems being radiation-cataract, which was treatable, and preexisting glaucoma, which in several patients was difficult to control.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16111578     DOI: 10.1016/j.ijrobp.2005.01.050

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

Review 1.  [New treatment options for iridociliary tumors].

Authors:  J M Mor; K R Koch; V Kakkassery; C Cursiefen; L M Heindl
Journal:  Ophthalmologe       Date:  2019-04       Impact factor: 1.059

Review 2.  Don't it make my blue eyes brown: heterochromia and other abnormalities of the iris.

Authors:  I G Rennie
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

3.  Proton therapy of iris melanoma with 50 CGE : Influence of target volume on clinical outcome.

Authors:  Aline I Riechardt; Bettina Karle; Dino Cordini; Jens Heufelder; Volker Budach; Antonia M Joussen; Johannes Gollrad
Journal:  Strahlenther Onkol       Date:  2017-06-19       Impact factor: 3.621

4.  Proton beam radiotherapy of uveal melanoma.

Authors:  Bertil Damato; Andrzej Kacperek; Doug Errington; Heinrich Heimann
Journal:  Saudi J Ophthalmol       Date:  2013-07

Review 5.  Review of clinical experience with ion beam radiotherapy.

Authors:  A D Jensen; M W Münter; J Debus
Journal:  Br J Radiol       Date:  2011-03-22       Impact factor: 3.039

6.  Multifocal iris melanoma treated with total anterior segment palladium-103 plaque radiation therapy.

Authors:  Vasileois Petousis; Paul T Finger; Tatyana Milman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-12-14       Impact factor: 3.117

7.  Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture.

Authors:  B Damato
Journal:  Eye (Lond)       Date:  2012-06-29       Impact factor: 3.775

8.  [Iridal color changing in ocular masquerade syndrome].

Authors:  S Waibel; K Pillunat; L Pillunat
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

9.  Baerveldt implant for secondary glaucoma due to iris melanoma.

Authors:  Annelie N Tan; Juliette G M M Hoevenaars; Carroll A B Webers; Bertil Damato; Henny J M Beckers
Journal:  Clin Ophthalmol       Date:  2010-05-06

10.  Proton beam therapy for presumed and confirmed iris melanomas: a review of 36 cases.

Authors:  Ahmed Rahmi; Hamid Mammar; Juliette Thariat; Gaelle Angellier; Joel Herault; Pierre Chauvel; Laurent Kodjikian; Philippe Denis; Jean Daniel Grange
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-20       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.